By Mitul Agarwal, CEO/FOUNDER at Pharmatradz.com
With 25 years working at the intersection of pharmaceutical innovation and global supply chains, I’ve witnessed a lot of “breakthrough” moments. But what’s happening with CRISPR gene therapy right now? This isn’t just another incremental improvement. This is the moment when science fiction became science fact—and it’s creating opportunities (and challenges) that will reshape our entire industry in coming years
On February 9, 2025, a seven-month-old baby named KJ received three infusions of a therapy that had never existed before August 2024.
Not “never existed for him.” Never existed. Period.
KJ was born with severe CPS1 deficiency, a genetic disorder so rare it affects only 1 in 1.3 million newborns. Without treatment, toxic ammonia would build up in his blood, destroying his liver and causing devastating neurological damage. The standard treatment? A liver transplant. But KJ was too small, too young, too sick.
So doctors at Children’s Hospital of Philadelphia did something unprecedented: They designed a custom CRISPR gene therapy specifically for KJ’s unique genetic mutation.
From identifying his specific mutation to delivering the first dose took just seven months.
Let that sink in. Seven months from diagnosis to custom-designed, FDA-approved, personalized genetic medicine.
KJ is now home, thriving, reaching his developmental milestones. And he’s not just a medical miracle—he’s proof that we’ve entered a completely new era of medicine.
Welcome to the CRISPR revolution. And if you’re in pharmaceutical manufacturing, sourcing, or business development, you need to pay very close attention to what’s happening.
Let’s start with the market reality:
- Current Market (2026): $4.95 billion
- 2035 Projection: $18.89 billion
- Growth Rate: 14.77% CAGR through 2035
- First Approved CRISPR Drug: CASGEVY (December 2023) - $2.2 million per treatment
- Patients Treated Globally: 250+ and accelerating rapidly
- Time to Develop Custom Therapy: 6-7 months (and getting faster)
But here’s what the numbers don’t tell you: This isn’t about one drug or one disease. This is a platform technology that can potentially cure thousands of genetic disorders.
The shift in our platform is impossible to miss:
- Gene therapy manufacturing inquiries up 30% year-over-year
- Viral vector production capacity requests skyrocketing
- CDMO partnerships for cell therapy facilities
- Reagent and enzyme API sourcing for CRISPR manufacturing
- Licensing inquiries for regional gene therapy products
One thing is crystal clear: Companies that position themselves in the CRISPR supply chain NOW will own the next decade. Those that wait will spend ten years playing catch-up.
On this date, the FDA approved CASGEVY (exagamglogene autotemcel), the world’s first CRISPR-based gene therapy.
This wasn’t just another drug approval. This was the moment when CRISPR—a technology that won the 2020 Nobel Prize—moved from laboratory bench to actual patient treatment.
CASGEVY treats sickle cell disease, a genetic blood disorder affecting approximately 100,000 Americans (predominantly Black patients) and millions more worldwide.
Here’s how it works:
- Patient’s stem cells are collected from their blood
- CRISPR-Cas9 edits the cells to increase fetal hemoglobin production
- Patient receives chemotherapy to clear space in bone marrow
- Edited cells are infused back into the patient
- The edited cells produce healthy blood cells - potentially for life
The results from clinical trials? Absolutely stunning.
- 29 out of 31 patients (94%) had NO severe vaso-occlusive pain crises for at least 12 consecutive months
- Patients who had been suffering monthly pain crises were pain-free
- No need for ongoing blood transfusions
- Quality of life transformed overnight
One patient in the trial told CBS News: “I can do things I never dreamed of doing. I can work, I can travel, I can live.”
That’s not symptom management. That’s a functional cure.
CASGEVY costs $2.2 million per patient for the one-time treatment.
Your first reaction is probably: “That’s insane. Nobody can afford that.”
But here’s the economic reality: The lifetime cost of managing sickle cell disease with traditional treatments averages $1.7 million—and that’s assuming the patient survives to average life expectancy, which many don’t.
A one-time cure for $2.2 million? From a healthcare economics perspective, it’s actually cheaper over a patient’s lifetime.
Insurance companies are wrestling with this right now. Do they pay $2.2 million upfront, or do they spread $1.7 million (plus inflation) over 30-40 years?
The answer will determine who gets access to these therapies. And that’s creating both ethical dilemmas and enormous business opportunities.
But yes there is a need of more affordable options specially for countries where insurance system are not that strong
Remember KJ, the baby I mentioned at the start? His story isn’t just heartwarming—it’s a blueprint for the future of medicine.
When KJ was diagnosed with severe CPS1 deficiency in August 2024, his prognosis was grim. The condition prevents the body from breaking down proteins, causing toxic ammonia buildup. Half of babies born with it die in infancy.
But KJ’s parents agreed to something unprecedented: letting doctors create a custom CRISPR therapy designed specifically for his unique mutation.
August 2024: KJ born, diagnosed immediately, DNA sequenced
September 2024: Research team begins designing custom base editor
October-December 2024: Safety testing, off-target analysis, manufacturing
January 2025: FDA approval (in just ONE WEEK)
February 2025: First dose administered at 7 months old
March-April 2025: Follow-up doses
June 2025: KJ goes home after 307 days in hospital
December 2025: KJ named in Nature’s “10 People Who Shaped Science in 2025”
Total time from diagnosis to treatment: 6-7 months.
And the team that did this—researchers from Children’s Hospital of Philadelphia, Penn Medicine, UC Berkeley’s Innovative Genomics Institute, and several biotech partners—says they can do it faster next time.
Before KJ, the assumption was that personalized genetic medicines would be: - Too expensive to develop for individual patients
- Too slow to manufacture
- Too risky for regulatory approval
- Only viable for large patient populations
KJ proved every single assumption wrong.
The Innovative Genomics Institute and their partners have created what they call a “cookbook” for on-demand CRISPR therapies. The platform can be adapted for different rare diseases, and each subsequent therapy gets faster and cheaper to produce.
The cost trajectory looks like this: - First patient: $2 million, 12 months development
- Third patient: Projected $100,000, 1 month development
- Scale: Platform approach could bring costs down to generic drug levels
This isn’t theoretical. The U.S. government just announced two major funding programs—THRIVE and GIVE—specifically to scale this approach to more patients.
We’re watching the birth of an entirely new pharmaceutical paradigm: personalized genetic medicines manufactured on-demand.
While the US was celebrating CASGEVY’s approval, China was quietly building a CRISPR empire.
Here are the facts that should concern every Western pharmaceutical executive:
- 27.2% of all global GLP-1 clinical trials are conducted in China (second only to US)
- First Chinese CRISPR drug approved: Innovent Biologics’ gene therapy in late 2024
- Massive government investment: Billions flowing into gene therapy infrastructure
- Manufacturing capacity: China is building specialized gene therapy production facilities at unprecedented scale
- Regulatory pathway: Faster approval process for gene therapies than Western markets
Real Example from Pharmatradz Platform: We’ve processed 10+ inquiries from companies looking to source CRISPR reagents, viral vectors, and manufacturing capacity from Chinese suppliers. The pricing is compelling—sometimes 40-50% lower than Western alternatives.
But here’s the complexity: If you’re targeting FDA or EMA markets, you need suppliers with the right certifications, documentation, and regulatory compliance. Not all Chinese manufacturers have that (yet).
However, for emerging markets—India, Brazil, Southeast Asia, Africa—Chinese CRISPR suppliers are becoming increasingly attractive options.
Within 5 years, we’ll likely see: - Low-cost Chinese CRISPR therapies flooding emerging markets
- Price pressure on Western gene therapy companies
- A bifurcated market: premium therapies for developed markets, affordable versions for everywhere else
Companies that build dual sourcing strategies now—Western suppliers for regulated markets, qualified Chinese suppliers for cost-sensitive markets—will have massive competitive advantages.
Here’s the dirty secret of the CRISPR revolution: We don’t have enough manufacturing capacity to meet demand.
Not even close.
Almost all gene therapies require viral vectors—modified viruses that deliver the genetic payload into cells.
The problem? Manufacturing viral vectors at commercial scale is: - Technically complex: Requires specialized bioreactors and purification systems
- Capacity-constrained: Only a handful of facilities globally can do it at GMP standards
- Expensive: Building a viral vector facility costs $100-300 million
- Time-consuming: 18-24 months from planning to production
Real Story from Our Platform: A mid-sized biotech came to us looking for a CDMO that could manufacture AAV vectors for their gene therapy candidate. They had $50 million in Series B funding and a promising Phase 2 candidate.
After searching our entire database and personally contacting 10+ CDMOs globally, we found: - Only 8 facilities with available AAV manufacturing capacity
- 7 of those 8 were fully booked until late 2026
- The one with capacity required a $5 million minimum commitment
- Lead time for first GMP batch: 14 months
Their competitor, who had locked in manufacturing capacity a year earlier, will launch 18 months ahead of them.
In gene therapy, manufacturing capacity is literally more valuable than the drug itself.
Even if you can manufacture the genetic payload, you still need to fill vials, package products, and maintain ultra-cold chain logistics.
Gene therapies often require: - Liquid nitrogen storage (-196°C)
- Specialized fill-finish equipment
- Clean room capabilities beyond standard pharma
- Chain of custody systems for patient-specific therapies
There are fewer than 10 facilities worldwide that can handle all these requirements at commercial scale.
CRISPR manufacturing requires highly specialized reagents: - Cas9 enzyme (or various base editors, prime editors)
- Guide RNA sequences (custom designed for each target)
- Lipid nanoparticles (for delivery)
- Cell culture media (for expanding edited cells)
- Quality control reagents (for testing off-target effects)
Many of these materials have only 2-3 qualified suppliers globally. A shortage in any one component can shut down your entire production.
Pharmatradz Insight: Companies that are securing long-term supply agreements for critical CRISPR reagents NOW are the ones who will have production certainty in 2026-2027.
CASGEVY was just the beginning. The pipeline of CRISPR therapies in development is absolutely massive.
- CASGEVY (Vertex/CRISPR Therapeutics) - Sickle cell disease and beta-thalassemia - $2.2 million
- LYFGENIA (bluebird bio) - Sickle cell disease - Approved December 2023
- Custom therapies - Baby KJ’s therapy, with more N-of-1 therapies in pipeline
The CRISPR therapy pipeline includes treatments for:
Blood Disorders: - Hemophilia A and B & Thalassemia
- Familial hypercholesterolemia
- ATTR amyloidosis
Metabolic Diseases: - Urea cycle disorders (proven with KJ)
- Glycogen storage diseases
- Lysosomal storage disorders
Cancer: - CAR-T cell enhancement with CRISPR
- Tumor-infiltrating lymphocytes (TILs) with gene editing
- NK cell therapies with CRISPR modifications
Infectious Diseases: - HIV cure strategies using CRISPR
- Hepatitis B functional cure
Cardiovascular: - PCSK9 editing for cholesterol
- ANGPTL3 editing for triglycerides
Neurodegenerative Diseases: - Huntington’s disease
- ALS (early research)
- Alzheimer’s (very early research)
Each of these represents multi-billion dollar market opportunities.
There are two fundamentally different approaches to CRISPR therapy:
Ex Vivo (Outside the Body): - Take cells out of patient
- Edit them in the lab
- Give them back to patient
- Examples: CASGEVY, CAR-T therapies
- Advantage: Can verify edits before giving back
- Disadvantage: Complex, expensive, requires stem cell harvest
In Vivo (Inside the Body): - Inject CRISPR directly into patient
- Editing happens inside the patient’s body
- Examples: Baby KJ’s therapy, liver-targeted therapies
- Advantage: Simpler, potentially cheaper, one injection
- Disadvantage: Can’t take back an edit once it’s made
The future is clearly moving toward in vivo CRISPR therapies. These are: - Faster to administer
- Don’t require hospitalization for weeks
- Can potentially be given in outpatient settings
- Much cheaper to manufacture
But in vivo therapies require sophisticated delivery systems—primarily lipid nanoparticles (LNPs)—and that’s creating massive demand for LNP manufacturing capacity.
While Big Pharma fights over the US and European markets, there’s a massive opportunity in regions most companies are ignoring.
Africa has: - 3+ million people living with sickle cell disease
- Highest prevalence rates in the world
- Minimal access to current treatments
- Only 3 bone marrow transplant centers on the entire continent
CASGEVY at $2.2 million is completely inaccessible to African patients. But what if you could produce a CRISPR-based sickle cell therapy for $100,000? Or $50,000?
That’s still expensive, but it moves into the realm of possibility for: - Government health programs
- International development aid
- Medical tourism models
- Premium private hospitals
Strategic Opportunity: License CRISPR technology for African markets with tiered pricing. Establish manufacturing partnerships in South Africa, Nigeria, or Kenya. Build the market before the multinational giants wake up to it.
India has a proven track record of taking expensive Western medicines and manufacturing them affordably at scale. It happened with HIV drugs, hepatitis C drugs, and cancer medications.
Could India become the “generic gene therapy” manufacturing hub for the world?
Consider: - Massive biotechnology talent pool
- Established GMP manufacturing infrastructure
- Cost advantages of 60-80% vs Western manufacturing
- Regulatory pathways for fast biosimilar approvals
- Large domestic market for beta-thalassemia, other genetic disorders
Real Observation: We’re already seeing Indian CDMOs invest in viral vector capabilities. The ones getting in early will capture enormous market share as patents expire and biosimilar gene therapies become viable.
Brazil’s pharmaceutical market is growing rapidly, yet gene therapy penetration is essentially zero.
Why Brazil is interesting for CRISPR: - 213 million population with significant genetic disease burden
- Growing middle class with health insurance
- Government interest in biotechnology investment
- Regional manufacturing hub potential for all of Latin America
- Relatively streamlined regulatory pathway through ANVISA
Pharmatradz Data: We’ve seen 3+ inquiries from Brazilian companies interested in licensing gene therapy technology or establishing manufacturing partnerships.
The companies that establish themselves in Brazil now will dominate the $500 million+ Latin American gene therapy market by 2030.
Let’s address the elephant in the room: Who gets access to $2 million therapies?
Current reality: - CASGEVY costs $2.2 million per patient
- Only available at a handful of authorized treatment centers
- Requires 2-6 months of treatment including hospitalization
- Not all insurance companies are covering it
- Predominantly available in the US and select European countries
This means: - ✅ Wealthy patients with good insurance: Access
- ✅ Clinical trial participants: Access
- ❌ Uninsured patients: No access
- ❌ Patients in developing countries: No access
- ❌ Poor patients without advocacy: No access
This creates a two-tier medical system where rich people can cure genetic diseases and poor people can’t.
That’s not just ethically troubling—it’s a recipe for social unrest and regulatory backlash.
Here’s what nobody wants to talk about: CASGEVY and other current CRISPR therapies only edit somatic cells (body cells). The edits don’t pass to children.
But CRISPR can also edit germline cells (sperm, eggs, embryos). Those edits WOULD pass to future generations.
The Chinese researcher He Jiankui infamously created CRISPR-edited babies in 2018, claiming he made them resistant to HIV. He was sentenced to three years in prison.
But the technology exists. And as CRISPR becomes more accessible, the temptation to use it for germline editing will grow.
Questions we’ll face in the next 5-10 years: - Should parents be able to edit out disease genes in their embryos?
- What about editing for enhanced traits (intelligence, athleticism)?
- Who decides what’s a “disease” worth editing vs. normal variation?
- How do we prevent “designer babies” for the wealthy?
These aren’t theoretical questions. They’re coming fast, and the pharmaceutical industry needs to have answers.
Countries are taking different approaches:
United States: - No federal law banning germline editing
- FDA won’t currently approve germline therapies
- Some states have their own restrictions
- Research is allowed but highly regulated
European Union: - Generally prohibitive toward germline editing
- Strong ethical oversight frameworks
- Focus on somatic cell therapies only
China: - Officially banned germline editing after He Jiankui scandal
- But enforcement is questionable
- Heavy investment in CRISPR research infrastructure
- Likely to be first to commercialize certain applications
Implication for pharma: Regulatory arbitrage will happen. Companies will manufacture in permissive jurisdictions and export to restrictive ones. The compliance complexity will be enormous.
Enough theory. Let’s talk strategy. Here’s what winning companies are doing to position themselves for the CRISPR revolution:
1. Lock In Manufacturing Capacity Yesterday
Seriously, if you’re in Phase 1 trials and don’t have CDMO capacity reserved for Phase 3, you’re already behind.
Action Items: - Reserve viral vector manufacturing capacity now (even at premium prices)
- Sign multi-year agreements with fill-finish providers
- Secure reagent supply with backup suppliers in different regions
- Consider building internal manufacturing for critical components
Pharmatradz Recommendation: Use platforms like ours to identify 3-5 CDMO options, then visit them in person. The facilities with the best equipment aren’t always the ones with the flashiest websites.
2. Plan for Tiered Pricing from Day One
Don’t assume every market will pay $2 million per dose.
Build your development plan with multiple pricing tiers: - Tier 1 (US/EU): Premium pricing, full support services
- Tier 2 (Emerging markets): Reduced pricing, basic support
- Tier 3 (Low-income countries): Cost-recovery pricing, partnerships with NGOs
Example: A sickle cell therapy priced at $2.2 million in the US, $500,000 in Brazil, $100,000 in Nigeria through government programs.
3. Pursue Platform Technologies, Not One-Off Drugs
Baby KJ’s therapy demonstrated the power of platforms. Instead of developing one therapy for one disease, develop: - A CRISPR platform for liver-targeted diseases
- A base editor platform for single-nucleotide mutations
- A lipid nanoparticle delivery platform for multiple payloads
Each subsequent therapy built on the platform gets cheaper and faster.
1. Invest in Gene Therapy Capabilities NOW
The manufacturing capacity shortage is real and will last for years. CDMOs that build capacity now will name their price.
What’s needed: - Viral vector production: AAV, lentivirus, adenovirus
- Cell therapy manufacturing: GMP cell culture facilities
- Fill-finish for frozen products: Ultra-cold chain capabilities
- Analytical testing: Gene editing verification, off-target screening
- Regulatory support: DMF preparation, IND filing assistance
ROI Reality: A gene therapy manufacturing facility with $150 million investment can generate $500 million+ in annual revenue by 2028 if built now.
2. Specialize in Niche Capabilities
You don’t need to offer everything. Pick one thing and be the best: - LNP manufacturing: Huge demand, few suppliers
- Base editor reagents: Critical need, limited sources
- Patient-specific manufacturing: The N-of-1 opportunity
- Small-scale GMP production: Perfect for rare diseases
Pharmatradz Insight: The CDMOs winning the most business aren’t the biggest—they’re the ones with unique capabilities that nobody else has.
3. Build Relationships with Academic Partners
Many breakthrough CRISPR therapies are coming out of academic labs (like KJ’s therapy from Penn/CHOP/UC Berkeley).
Academic researchers need commercial manufacturing partners. But they don’t know who to trust.
Strategy: - Sponsor academic conferences
- Offer pilot manufacturing grants
- Collaborate on NIH SBIR/STTR grants
- Provide free analytical testing for researchers
The academic labs you help today will bring you their commercial programs tomorrow.
1. The Enzyme Opportunity Is Massive
CRISPR manufacturing requires: - Cas9 nuclease (multiple variants)
- Base editors (adenine, cytosine)
- Prime editors (next generation)
- Guide RNA synthesis reagents
- Delivery vehicle components
Current suppliers are mostly small biotech companies. There’s room for large-scale, GMP-certified manufacturing.
Market Size: The CRISPR reagent market alone is projected to exceed $3 billion by 2030.
2. Focus on Quality Documentation
Gene therapy manufacturers need suppliers with: - Complete DMF files
- Batch-to-batch consistency data
- Impurity profiles
- Stability studies at multiple temperatures
- Regulatory filing support
If you’re the supplier that can provide all this documentation ready-to-submit, you can charge premium prices.
3. Offer Custom Synthesis Services
Every CRISPR therapy needs custom guide RNAs designed for specific genetic targets.
There’s enormous demand for: - Fast custom RNA synthesis (1-2 week turnaround)
- High-purity, GMP-grade material
- Analytical verification
- Flexibility on order sizes
Companies that can synthesize custom guide RNAs quickly and reliably will have more business than they can handle.
1. Become the Gene Therapy Matchmaker
The complexity of gene therapy manufacturing means companies desperately need help finding: - Qualified CDMOs with availability
- Specialized reagent suppliers
- Fill-finish providers
- Analytics and testing labs
- Regional manufacturing partners
Platforms that can connect these dots efficiently will capture enormous value.
2. Provide Market Intelligence
Gene therapy companies need real-time data on: - CDMO capacity and booking status
- Reagent pricing and availability
- Regulatory developments by region
- Clinical trial results and competitor progress
The platform that provides this intelligence will become indispensable.
3. Enable Regional Partnerships
The tiered pricing model means gene therapy companies need manufacturing partners in multiple regions.
Platforms that facilitate: - Technology licensing for emerging markets
- Manufacturing partnerships across borders
- Regulatory guidance for different jurisdictions
Will enable the global scale-up of gene therapies.
Let me paint a picture of what I think the CRISPR landscape will look like in 2035:
By 2035: - 50+ CRISPR therapies will be FDA-approved
- 100,000+ patients will have received CRISPR treatments
- Outpatient CRISPR injections will be standard for many conditions
- Costs will drop to $100,000-500,000 range for most therapies
Gene therapy won’t be exotic—it’ll be just another treatment option.
We’ll see: - 10-15 mega-CDMOs dominating viral vector production
- Specialized regional manufacturers for specific therapy types
- Platform companies offering end-to-end gene therapy manufacturing
- Asia-Pacific manufacturing hubs competing with Western CDMOs
The companies that build capacity now will be the giants of 2035.
Instead of patient-specific treatments: - Universal donor cell lines edited with CRISPR
- Frozen, ready-to-use CAR-T cells
- Multi-dose vials of in vivo CRISPR therapies
- Pharmacy-dispensed gene therapies for common conditions
This will drop costs dramatically and expand access.
Expect: - Accelerated approval pathways for gene therapies
- Platform approval models (approve the platform once, then individual applications faster)
- International harmonization of gene therapy regulations
- Real-world evidence replacing some clinical trial requirements
The FDA approval time will shrink from years to months.
Society will wrestle with: - Germline editing - Will some countries allow it?
- Enhancement vs. treatment - Where’s the line?
- Access inequality - How do we ensure fair distribution?
- Insurance coverage mandates - Should gene therapy be required coverage?
These debates will shape which therapies get developed and who can access them.
The CRISPR revolution is here. It’s not coming—it’s already happening.
But here’s what history teaches us about technological revolutions:
The companies that win aren’t the ones with the best technology.
They’re the ones that position themselves in the right part of the supply chain at the right time.
In the next 3-5 years: - Gene therapy manufacturing capacity will be worth more than gold
- Reagent suppliers will print money
- CDMOs with viral vector capabilities will name their price
- Regional manufacturing partners will open massive markets
- Companies that secure supply chains now will dominate
The window to position yourself is right now.
In 2027, when every CDMO is booked solid, every reagent supplier is on allocation, and your competitor launches 18 months before you because they secured capacity in 2025—it’ll be too late.
What are you waiting for?
At Pharmatradz.com, we’re connecting the pharmaceutical companies and CDMOs who will build the gene therapy future.
🏭 Find CDMO Partners - Connect with viral vector manufacturers, cell therapy facilities, and fill-finish providers
🔬 Source CRISPR Reagents - Cas9, guide RNAs, lipid nanoparticles, and specialized enzymes
📊 Get Capacity Intelligence - Real-time data on CDMO availability and booking status
🤝 License Technology - Find regional manufacturing partners for emerging markets
📋 Access Regulatory Expertise - Navigate FDA, EMA, and emerging market approvals
📈 Access Gene Therapy Clients - Connect with biotechs actively seeking manufacturing capacity
🌐 Showcase Your Capabilities - Highlight viral vector, cell therapy, or analytical services
💼 Close Deals Faster - Pre-qualified clients with verified funding and timelines
🎯 Target Opportunities - Filter by therapy type, phase, and regional requirements
📁 List Your CRISPR Products - Enzymes, guide RNAs, delivery vehicles, and specialty reagents
🔍 Find Verified Buyers - Gene therapy companies with immediate needs
💰 Premium Pricing Power - Limited competition in specialized CRISPR reagents
🚀 Scale Your Business - Join [X]+ suppliers serving the gene therapy market
✓ Specialized Network - Focused on gene therapy supply chain partners
✓ Verified Capabilities - Pre-screened for GMP, regulatory compliance, and capacity
✓ Real-Time Intelligence - Know who has availability, not who might
✓ Global Reach - Connect with partners across US, Europe, Asia, and emerging markets
✓ Expert Guidance - Our team understands gene therapy manufacturing complexity
✓ Confidential Platform - Protect your proprietary programs while sourcing partners
Visit Pharmatradz.com Now
Your Trusted Partner for Licensing Finished Products and APIs
Because in the fastest-growing sector of pharmaceutical history, the right partnerships aren’t just valuable—they’re essential.
Mitul Agarwal is the CEO/Founder at PharmaTradz, where he has helped 2+ pharmaceutical and biotech companies navigate the complex landscape of gene therapy manufacturing, sourcing, and partnerships. With 25 years of experience in pharmaceutical supply chain management and emerging therapeutic technologies, has a front-row seat to the CRISPR revolution transforming medicine. He specializes in connecting innovative biotechnology companies with the manufacturing partners and suppliers they need to bring breakthrough genetic medicines from bench to bedside. Connect with him on LinkedIn at https://www.linkedin.com/in/mitul-aga-b2b709227/
Keywords: CRISPR gene therapy, CASGEVY, gene editing therapeutics, viral vector manufacturing, AAV production, gene therapy CDMOs, CRISPR reagents, Cas9 enzyme suppliers, lipid nanoparticles, cell therapy manufacturing, sickle cell gene therapy, rare disease treatments, personalized medicine, gene therapy market, viral vector supply chain, CRISPR manufacturing, gene editing supply chain, pharmaceutical B2B platform, biotech partnerships
Last Updated: February 2026
Disclaimer: The information presented in this article is for informational and educational purposes only. While every effort has been made to ensure data accuracy and reliability, readers are advised to independently verify all figures, regulations, and market insights before making any business or investment decisions.